Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials

被引：4

作者：

Rojas-Hernandez, Cristhiam M. ^{[1
]}

Oo, Thein Hlaing ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Sect Thrombosis & Benign Hematol, 1515 Holcombe Blvd,Unit 1464, Houston, TX 77030 USA

来源：

DRUGS | 2019年 / 79卷 / 06期

关键词：

CLINICAL-PRACTICE GUIDELINES; MAJOR ABDOMINAL-SURGERY; PULMONARY-EMBOLISM; ACTIVE MALIGNANCY; SUBGROUP ANALYSIS; AMERICAN SOCIETY; HIGH-RISK; PROPHYLAXIS; THROMBOPROPHYLAXIS; RIVAROXABAN;

D O I：

10.1007/s40265-019-01084-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer accounts for 20% of all venous thromboembolism (VTE) worldwide and cancer patients are at four- to sevenfold increased risk of thrombosis compared to non-cancer patients. VTE is also a morbid complication of cancer and its incidence is rising. Thrombosis is also a second leading cause of death in cancer patients. The standard of care management for the prevention and treatment of cancer-associated thrombosis (CAT) remains the administration of low-molecular-weight heparins (LMWHs). In the last decade, five direct oral anticoagulants (DOACs), dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban, have been approved for the treatment and prevention of VTE in the general patient population. In this review, we discuss the results of the already published clinical trials with DOACs in the treatment of CAT and the ongoing clinical trials with DOACs in the prevention and treatment of CAT.

引用

页码：621 / 631

页数：11

共 50 条

[21] Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism
Riva, Nicoletta
Ageno, Walter
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (05) : 1035 - +
[22] In the Pipeline: New Oral Anticoagulants for the Prevention of Venous Thromboembolism
Farley, T. Michael
Lewis, Daniel
Macaulay, Tracy E.
ORTHOPEDICS, 2009, 32 (01) : 35 - 39
[23] Comparative Effects Between Direct Oral Anticoagulants for Acute Venous Thromboembolism: Indirect Comparison From Randomized Controlled Trials
Li, Guowei
Zeng, Jie
Zhang, Junguo
Thabane, Lehana
FRONTIERS IN MEDICINE, 2020, 7 : 1 - 15
[24] Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis
Wu, Shuyi
Lv, Meina
Chen, Jiana
Jiang, Shaojun
Chen, Mingrong
Fang, Zongwei
Zeng, Zhiwei
Qian, Jiafen
Xu, Wenlin
Guan, Chengfu
Zhang, Jinhua
SUPPORTIVE CARE IN CANCER, 2022, 30 (12) : 10407 - 10420
[25] Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention arm Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials
Chen, Jiana
Lv, Meina
Wu, Shuyi
Jiang, Shaojun
Xu, Wenlin
Qian, Jiafen
Chen, Mingrong
Fang, Zongwei
Zeng, Zhiwei
Zhang, Jinhua
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2022, 63 (03) : 465 - 474
[26] Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
Ay, C.
Beyer-Westendorf, J.
Pabinger, I.
ANNALS OF ONCOLOGY, 2019, 30 (06) : 897 - 907
[27] The use of novel oral anticoagulants in cancer patients with venous thromboembolism
Karakatsanis, Stamatis J.
Roumpi, Aikaterini
Syrigos, Konstantinos N.
SEMINARS IN ONCOLOGY, 2016, 43 (06) : 655 - 665
[28] Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism
Zeng, Jie
Zhang, Xuhui
Lip, Gregory Y. H.
Shu, Xiaochen
Thabane, Lehana
Tian, Junzhang
Li, Guowei
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
[29] Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants
Wharin, Caitlin
Tagalakis, Vicky
BLOOD REVIEWS, 2014, 28 (01) : 1 - 8
[30] Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants
Davide Imberti
Raffaella Benedetti
Walter Ageno
Internal and Emergency Medicine, 2013, 8 : 667 - 672

← 1 2 3 4 5 →